Jagsonpal Pharmaceuticals Ltd. · NSE:JAGSNPHARM
Jagsonpal Pharmaceuticals — Q1 FY26 Earnings Presentation
21 slides from Jagsonpal Pharmaceuticals's earnings presentation, Jul 26, 2025
Slide 1: Revised Investor Presentation filing letter to exchanges
JAGSONPAL PHARMACEUTICALS LIMITED Corporate Office: Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar, y -i Sector-18, Gurugram -122015, Haryana (India) akht UAGSONPAL! Ph.: +91 124 4406710; E-mail: info@jagsonpal.com; Website: www.jagsonpal.com CIN. : L74899DL1978PLC009181 A CSR Initi
Slide 2: Jagsonpal Pharmaceuticals announces Q1FY26 Results
Jagsonpal Pharmaceuticals announces Q1FY26 Results Q1FY26 Revenue up 23% YoY to ₹756 Mn, EBITDA at ₹157 Mn with 21% margin; PAT soars 2x to ₹108 Mn. Gurugram, July 26, 2025: Jagsonpal Pharmaceuticals Limited (BSE: 507789, NSE: JAGSNPHARM) today announced the unaudited financial results for the quart
Slide 3: CEO commentary and About Jagsonpal Pharmaceuticals
Commenting on the performance for the quarter, Manish Gupta, Managing Director and CEO, Jagsonpal Pharmaceuticals Limited said, “We have started FY 26 on a strong note with growth across all parameters. While our Revenue grew 23.1% to Rs. 756 Mn, operating EBITDA was at Rs. 157 Mn, up by 24.1%. The
Slide 4: Jagsonpal Pharmaceuticals Limited Q1FY26
Jagsonpal Pharmaceuticals Q1FY26 Limited Investor Presentation July 2025
Slide 5: Safe Harbor
Safe Harbor UAGSONPAL! This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance.
Slide 6: Management Commentary
Management Commentary B UJAGSONPALI '' We have started FY 26 on a strong note with growth across all parameters. While our Revenue grew 23.1% to Rs. 756 Mn, operating EBITDA was at Rs. 157 Mn, up by 24.1%. The continued scale up is an outcome of our disciplined and effective execution of our strateg
Slide 7: Q1FY26 Performance
Q1FY26 Performance 4
Slide 8: Strong start to Q1FY26; PAT doubles
Strong start to Q1FY26; PAT doubles Healthy Sales Growth across key brands Achieved Rs. 756 Mn in quarterly sales, marking a robust 23.1% growth compared to Q1FY25. Strong brand equity boosting gross margins Gross Margin increased by 80 bps to 64.4%. Operating EBITDA up 24.1% Op. EBITDA of Rs. 157 M
Slide 9: Financial Highlights: Q1FY26
Financial Highlights: Q1FY26 B HJAGSONPAL! (All values in Rs. Mn) Revenue from Operations Gross Profit & Margin (%) EBITDA & Margin* (%) PAT & Margin (%) Q1FY25 ■ Q1FY26 r·-·-·-·-·-·-·-·~I I r-·-·-·-·-·-·-·-··I !I I I 756 !I 487 I 614 ! 157 391 ! I !I 127 I 108 ! I i ! I 53 i I 63.7% 64.4% I i 20.6%
Slide 10: Financial Results: Q1FY26
El Financial Results: Q1FY26 (All values in Rs. Mn) Particulars Q1FY26 Q4FY25 Q-O-Q Q1FY25 Y-O-Y Revenue from Operations 756 586 29.1% 614 23.1% Total Expenses 599 489 22.6% 488 22.8% EBITDA* 157 97 61.9% 127 24.1% EBITDA Margin* 20.8% 16.6% 420 bps 20.6% 17 bps Other Income 28 28 2.0% 14 95.6% ESOP
Slide 11: Key Balance Sheet Items
El Key Balance Sheet Items (All values in Rs. Mn) Particulars 30-Jun-25 31-Mar-25 QoQ 30-Jun-24 YoY Shareholders Funds 2,535 2,399 5.7% 1,956 29.6% Tangible Assets 6 6 (2.7)% 9 (35.1)% Intangibles 837 856 (2.2)% 913 (8.3)% Right of Use Assets 80 82 (2.7)% 81 (1.5)% Assets Held for Sale - - - 172 - F
Slide 12: About the Company
About the Company 9
Slide 13: Built for Scale. Positioned for Performance.
Built for Scale. Positioned for Performance. 1. Therapy powerhouse with deep domain expertise Spanning branded generics, trade generics & OTC; Ranked #8 in CVM 2. 100% India Centric Business PAN India presence; Sub-chronic Presence 9.4% 27.8% 03. Lean Operations: Asset Light Model Revenue CAGR (FY21
Slide 14: Strong Presence in Key Therapies
Strong Presence in Key Therapies iUAGSONPAL Ranked 8th in Corporate CVM (as per CMARC RPM) Gynecology Orthopedics 7th as per CMARC RPM in CVM 2nd as per CMARC RPM in CVM Reaching ~90% of the Gynecologists 01 02 Reaching ~80% of the nationwide, engagement with 35,000 Orthopedists through cons
Slide 15: Building A High-impact Asset Light Model
Building A High-impact Asset Light Model D UAGSONPAL! Capital Intensive Activities - Out-Sourced 0- ~i~ - lliiiiiiii' Ideation PAN-India Distribution o In-house Ideation For Research & Contract o 1000+ Medical Reps for Innovative Drug Concepts. Development Manufacturing brand promotion 1-2 New Produ
Slide 16: Strategic Pillars
Strategic Pillars UAGSONPAL! Innovation - Large, well Niche Molecules, trained Work Dominant Market Force of 1000+ Share Medical Reps Lean Operations: Inorganic Growth Asset Light Powered by Model Strategic Acquisition 13
Slide 17: MySakhi Initiative: Where Business Meets Social Impact
MySakhi Initiative: Where Business Meets Social Impact Real World Impact: Beyond The Bottom Line Shaping the Driving Empowering Transforming Future Menopause Women Through Hygiene Access Awareness MySakhi.in Expanding outreach Deliver impactful A dedicated website Built modern with self-testing kits
Slide 18: 5-Year journey in a nutshell
5-Year journey in a nutshell HJAGSONPAL (All values in ₹ Mn) Revenue (Rs Mn) Operating EBITDA (Rs Mn)* I"'·-·-·-·-·-·, 2,687 579 2,367 2,176 2,087 434 1,879 364 250 191 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 L--•-•-•-•-•.J PAT (Rs Mn) Margins built to last I"'·-·-·-·-·-·, .-·-·-·-·-·- 375
Slide 19: Lean and Efficient Business Model
Lean and Efficient Business Model D UAGSONPAL! 16.1% 13.2% ir·-·-·-·-·-·-·-·••I ir·-·-·-·-·-·-·-·••I • • I • I • • I 60% I i • !I i 57% --r---_ !! / I 10.5% • I • I • • I I • • I 50% I • • I • I I • I • 6.7% • I I • • I I • • I i ! 351 ----- I • • I I • i !I • I I • 34% • I • i !I 28% i !I 249 231 •
Slide 20: Growth Outlook
Growth Outlook UAGSONPAL! The 3-Pronged Growth Strategy Outlook – FY26 and Beyond New Product Launch Q1FY26 17 bps 23%+ Niche, Innovation driven OPM growth Launch 4-6 products annually, driving market Revenue Growth (Pre- ESOP) engagement and revenue FY26 Outlook Volume Growth 20%+ 15%+ Sales
Slide 21: Thank You
D UAGSONPALi nk You Feel free to reach out to us if you have any questions. JAGSONPAL PHARMACEUTICALS LTD. INVESTOR RELATIONS Corporate Office: Nimai Tower, 3rd Floor, Soumya Chhajed Plot No. 412-415, Phase-IV, Udyog Vihar, Email: soumya@goindiaadvisors.com Gurugram -122015, Haryana (India) Ph: +91
Jagsonpal Pharmaceuticals — Q1 FY26 Earnings Presentation on 6ix